The project, rolled out through Boehringer Ingelheim’s diabetes alliance with pharmaceutical company Eli Lilly and Co., will develop a risk model to predict the likelihood of three health outcomes associated with Type 2 diabetes: cardiovascular death, kidney failure and hospitalization for heart failure.
The researchers will develop the model using de-identified data from Geisinger’s EHR. The ultimate goal is to create a model that informs personalized treatments for patients with Type 2 diabetes.
“We hope the knowledge gained from this predictive model can help healthcare providers better target their treatment recommendations for people with Type 2 diabetes and, as a result, lower their risk for these serious diabetes-related consequences,” said Brent Williams, PhD, a research investigator at the Geisinger Center for Health Research.
More articles on data analytics & precision medicine:
8 things to know about gene-editing tech CRISPR
Louisiana State U, Moffitt Cancer Center partner to address racial disparities in precision medicine
Survey: Healthcare execs name data analytics, population health among top challenges for 2018
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
